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ABSTRACT Background. In Pakistan, there is no 
mechanism to monitor the drug promotional 
campaign by pharmaceutical industry despite the fact 
that there is enough evidence that irrational 
pharmacotherapy is increasingly encountered even in 
the developed countries due to unethical practices of 
pharmaceutical promotion. Objectives. To audit the 
drug promotional claims made by the pharmaceutical 
companies in Pakistan. Methods. Drug promotional 
pamphlets and brochures containing claims for the 
drugs, which were circulated by the pharmaceutical 
representatives were collected from 122 general 
practitioners (GPs) from Karachi and Larkana cities 
of the Sindh Province. The claims were critically 
analyzed and audited with the help of currently 
available evidence in the medical literature. Results. 
345 distinct advertisements covering 182 drugs from 
different manufacturers were critically analyzed for 
information content. Sixty two out of 345 (18%) of 
the reviewed advertisements were adjudged to be 
misleading / unjustifiable, which were again 
classified as, exaggerated (32%), ambiguous (21%), 
false (26%), and controversial (21%). The primary 
source of information (approximately 78%) about the 
newly launched drugs for the GPs was found to be 
the pharmaceutical representatives followed by 
hospital doctors (5%) and colleagues (5%). 
Furthermore, 110 (90%) GPs were of the view that 
the drug promotion has definitely an influence on 
their prescribing pattern. Conclusions. Since GPs in 
Pakistan rate pharmaceutical companies as their 
primary source of information regarding drugs, it can 
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be anticipated that inappropriate advertisement 
claims would lead to irrational prescribing if 
physicians had no any other information to follow. 
INTRODUCTION 
The accuracy and usefulness of drug advertisements 
has been the subject of debate for more than a 
century now (1). According to World Health 
Organization’s (WHO) criteria for medicinal drug 
promotion, “promotion refers to all the informational 
and persuasive activities of manufacturers and 
distributors, the effect of which is to induce the 
prescription, supply, purchase and / or use of 
medicinal drugs” (2). Drug promotion and marketing 
make up a very large part of the activities of 
pharmaceutical companies in Pakistan. For the drug 
promotion, in addition to other activities, companies 
usually use the written material supposedly showing 
all the good and bad aspects about the concerned 
drug. These advertisements can be highly informative 
as long as they are critically appraised (3). However, 
when these are accepted without any question, can 
contribute to irrational prescribing. Ideally, drug 
promotional literature should provide health care 
professionals with substantial information. However, 
the information contained in promotional material 
may be inadequate (4) or altogether inaccurate (5). 
Undoubtedly, the pharmaceutical promotional 
activities have powerful influences on prescribing 
behavior of the clinicians although this influence may 
be more subliminal rather than overt (6, 7). 
 In an attempt to support and encourage the 
improvement of health care through the rational use 
of drugs, WHO has published ethical criteria for 
medicinal drug promotion and has recommended 
their implementation to its member states. As 
recommended in this document, all promotion-
making claims concerning medicinal drugs should be 
reliable, accurate, truthful, informative, balanced and 
up to date, capable of substantiation and in good 
taste. These should not contain misleading or 
unverifiable statements or omissions likely to induce 
medically unjustifiable drug use or to give rise to 
undue risks. 
 Being a member state of the United Nations 
Organization, efforts to regulate drug promotions in 
Pakistan were also initiated with the promulgation of 
the Drug Licensing, Registering and Advertising 
Rules by the Ministry of Health, Government of 
Pakistan. However, there is no mechanism to monitor 
the drug promotional campaign by pharmaceutical 
industry in Pakistan despite the fact that there is 
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enough evidence that rational drug utilization 
problems are increasingly encountered even in 
developed countries due to unethical practices of 
pharmaceutical promotion (8, 9). 
 Since promotional activities influence the 
prescribing behavior of the health care providers 
(10), it is of utmost importance to critically analyze 
the claims made in the promotional material of the 
drugs. Internationally, aspects of contents in 
pharmaceutical advertising pertinent to evidence-
based decision-making have been studied (11-13). 
The extent to which pharmaceutical companies 
promote the merits of their products and whether 
such claims are supported by evidence, has not been 
studied in Pakistan. The results of the present 
analytical study show that unethical and biased 
claims regarding the medicinal products are rampant 
in Pakistan. These drug promotions influence the 
prescribing behavior of the General Practitioners 
(GPs) thus accounting for one of the potentially 
major causes of irrational prescription. 
METHODS 
This was a descriptive study based on critical 
appraisal of drug promotional brochures, and on a 
questionnaire administrated from the GPs. 
 Drug promotional pamphlets and brochures 
containing claims for the drugs, which were 
circulated by the pharmaceutical representatives were 
collected from the clinics of 122 GPs. Since in 
Pakistan, we do not have a data base of the practicing 
GPs, randomization was not possible, therefore, the 
sampling units consisted of convenient areas of one 
big city (Karachi) and one relatively smaller town 
(Larkana) of the Sindh Province. The claims, which 
were written on those brochures were critically 
analyzed and audited by one 
Physician/Pharmacologist (DKR) with the help of 
currently available evidence in the medical literature. 
The medical literature consisted of published 
research articles retrievable from the Pubmed. 
Literature search was done for each claim by putting 
appropriate key words. All claims were adjudged 
misleading / unjustifiable, which were not supported 
by available evidence. The misleading / unjustifiable 
claims were further classified as follows: 
 1. Exaggerated: when a minor advantage of a 
drug was unnecessarily magnified showing 
exaggerated applications. 
 2. Ambiguous: when a merit of a drug in a 
particular circumstance was extrapolated erroneously 
to other situations. 
 3. False: when the claim in question was totally 
wrong. 
 4. Controversial: when the claim in question was 
supported by some scientific evidence. However, 
contradictory reports were also found challenging the 
validity of the claim. Overall, those claims were 
placed in this category, which are yet to be proven. 
 A structured questionnaire was also administered 
from the GPs from where the promotional material 
was collected. Questionnaire was developed and 
piloted before the study was started and the amended 
version was used in the main study. The 
questionnaire was designed to gather data about the 
sources of information regarding the drugs and the 
knowledge, attitude and beliefs of the GPs regarding 
medicinal drug promotion. 
RESULTS 
A. Appraisal of drug advertisements 
Three hundred and forty five distinct advertisements 
covering 182 drugs from different manufacturers 
were randomly collected from the GPs and critically 
analyzed for information content. The total number 
of claims in all 345 advertisements was 1035. This 
study focused mainly on the authenticity of the 
claims made by the pharmaceutical companies. Sixty 
two out of 345 (18%) reviewed advertisements were 
adjudged to be misleading / unjustifiable, which were 
again classified as: 
1. Exaggerated claims (32% of the unjustifiable 
claims): As shown in Table 1, many pharmaceutical 
companies in Pakistan, local as well as multinationals 
were found having the tendency to exaggerate certain 
facts about their products. One example of such 
exaggerated claim was made for a brand of 
loratadine, which states that this drug “provides 
alertness without sedation all day long” or “provides 
quick relief without sedation thus ensures the high 
activity of performance”. These are false as well as 
exaggerated claims. Admittedly, loratadine is 
relatively less sedating than some of the conventional 
anti-histamines but not absolutely non-sedating (14). 
Furthermore; we can not think of any mechanism by 
which loratidine can provide alertness or ensure the 
high activity of performance. In yet one more claim 
for a drug, which is a calcium supplement, it is stated 
that this product “controls and prevents typical 
disorders of pregnancy: low back pains, leg cramps, 
lower abdominal pain”. This claim is merely made on 
assumptions and there is no study and clinical 
evidence available to support such a claim.  
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Table 1: List of exaggerated promotional claims by pharmaceutical companies in the light of scientific evidence. 
Drug Pharmacological 
Class 
Claim Anti-claim statement Remark 
Alphacalcidol Vitamin D3 
precursor 
For the treatment and 
prevention of 
osteoporosis 
Only tried in corticosteroid-induced 
osteoporosis (15) 
Exaggerated / 
ambiguous 
Amoxicillin Penicillin Absence of side effects Although relatively safer, this drug is 
not devoid of side effects 
Exaggerated 
Bromazepam Anxiolytic Restores confidence It is anxiolytic. Has nothing to do with 
the lack of confidence associated with 
personality 
Exaggerated 
Buclizine Anti-histamine For anorexic child Appetite stimulation and weight gain 
have been reported as side effects in 
few studies (16), but we could not find 
the anorexia in children as the 
approved use of this drug. 
Exaggerated/ 
controversial 
Domperidone Anti-emetic Indicated in non-specific 
abdominal pain 
Only useful in abdominal pain 
associated with diabetic gastropathy 
(17) 
Exaggerated 
Domperidone Anti-emetic Provides relief in 
flatulence 
Effective in flatulence in a subset of 
patients with irritable bowel syndrome 
(18) 
Exaggerated 
Duxil Neuroprotective Improves memory Limited data in a subset of aged 
population (19) 
Exaggerated 
Glibenclamide Sulfonylurea anti-
diabetic 
Prevents diabetic 
complications 
Not directly. May delay the 
complications through optimum blood 
glucose control 
Exaggerated 
Glimepiride Sulfonylurea anti-
diabetic 
Restores physiological 
insulin release pattern 
during meals and exercise
The study quoted by the advertisement 
has shown only the effect of drug after 
meals not during or after exercise (20) 
Exaggerated 
Hydrocortisone 
sodium succinate 
Corticosteroid Life saving in 
anaphylactic reaction 
Steroids are never life saving in 
anaphylaxis. They are used once the 
condition has stabilized with other 
agents (21) 
Exaggerated 
Lactulose Laxative Indicated as a first line 
treatment of all types of 
constipation 
Lack of evidence Exaggerated 
Loratadine  H1-receptor 
antagonist  
Provides quick relief 
without sedation thus 
ensures the high activity 
of performance  
Causes less but definite sedation (14) Exaggerated 
Losartan Angiotensin 1 
receptor antagosist 
Better tolerability than 
other anti-hypertensives 
In what respect? No evidence Exaggerated/ 
False 
L-ornithine L-
aspartate 
Hepatoprotective A scientifically proven 
therapy for all liver 
disorders and more….. 
Has role in hepatic encephalopathy but 
not all liver disorders (22) 
Exaggerated 
Mecobalamin  The most effective 
treatment for peripheral 
neuropathy 
Mildly effective in only diabetic 
peripheral neuropathy (23) 
Exaggerated 
J Pharm Pharmaceut Sci (www.cspsCanada.org) 9(1):50-59, 2006 
  
 
 
 
53 
Mediforte Multivitamin 
preparation 
Improves quality of life 
in general weakness 
Can help if weakness is due to some 
vitamin deficiency 
Exaggerated 
Methotrexate Anti-metabolite Works through its anti-
metabolite and anti-
neoplastic actions 
How these two actions are different 
from each other is not clarified. 
Exaggerated 
Metronidazole+ 
furazolidone 
Anti-protozoal/anti-
bacterial 
The magic combination 
for all kinds of diarrhoea 
All kinds of diarrhoea can not be 
treated by this combination for 
example travelers’ diarrhoea or 
diarrhea associated with irritable bowel 
syndrome 
Exaggerated 
Nimodipine Ca2+ channel 
antagonist 
The effective treatment 
for senile dementia 
Although little benefit has been 
observed in selected patients, its use is 
not justified as anti-dementia drug (24) 
Exaggerated 
Vitamin E Vitamin supplement Scientific approach to 
treat muscle cramps 
Limited role in non-specific muscle 
cramps (25) 
Exaggerated 
 
 
Table 2: List of ambiguous promotional claims by pharmaceutical companies in the light of scientific evidence. 
Drug Pharmacological 
Class 
Claim Anti-claim statement Remark 
Bromazepam Anxiolytic Normalizes blood pressure Limited data in a subset of 
hypertensive population (26) 
Ambiguous 
Bromazepam Anxiolytic Most effective in the treatment of 
anxiety states without affecting 
intellectual functions 
Lack of evidence Ambiguous / 
exaggerated 
Famotidine H2 receptor antagonist The H2 receptor antagonist with 
predictable response 
This is true for other H2 
receptor antagonists as well 
Ambiguous 
Fosfomycin Antibiotic First line for all kinds of infections Strange claim. No evidence Ambiguous 
Lansoprazole Proton pump inhibitor Supreme in its class In what respect?? Ambiguous 
Lisinopril ACE inhibitor No prodrug Then what? Is it a benefit? Ambiguous 
Losartan Angiotensin 1 receptor 
antagosist 
More effective control of blood 
pressure 
More effective than what?? Ambiguous 
Mecobalamin Vitamin B12 analogue Effective in all kinds of nerve 
disorders 
Which disorders?? Ambiguous 
Mecobalamin Vitamin B12 analogue Helps repair the damaged nerves How? No evidence Ambiguous 
Methotrexate Anti-metabolite Works more quickly than 
commonly known drugs in 
rheumatoid arthritis 
Compared to what? Ambiguous 
Metoclopramide Anti-emetic Specific behavioural effect on 
digestive system  
Incomprehensible claim Ambiguous 
Mupirocin Anti-bacterial More effective that other topical 
and systemic antibiotics in the 
treatment of skin infections 
Lack of evidence Ambiguous / 
exaggerated 
Ranitidine H2 receptor antagonist The most comprehensive treatment 
of duodenal and gastric ulcer 
In what terms?? Ambiguous 
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2. Ambiguous claims (21% of the unjustifiable 
claims): During analysis, we encountered some very 
vague statements about the drugs as presented in 
Table 2. These statements may be only half of the 
truth resulting in the misleading and misguiding of 
the physicians. For instance, there was an interesting 
claim about the use of bromazepam, which was being 
promoted for the normalization of blood pressure. To 
support the claim, a paper was quoted (26). This 
study was conducted on a limited number of patients 
with mild hypertension. We could not find any other 
study complementing the findings of this report. 
Based on a single isolated study, hypertension can 
not be claimed as an approved use of bromazepam. 
 
Table 3: List of false promotional claims by pharmaceutical companies in the light of scientific evidence. 
Drug Pharmacological Class Claim Anti-claim statement Remark 
Atenolol β-adrenergic blocker No risk of bronchoconstriction Risk of bronchoconstriction is 
there (27) 
False 
Betahistine H3-receptor antagonist Improves neurotransmission in 
brain 
The study quoted by the 
advertisement shows the 
characterization of histamine 
receptors in vascular tissue (28) 
False 
Betahistine H3-receptor antagonist Does not sedate The study quoted by the 
advertisement does not support the 
claim (29) 
False 
Calcium 
supplement 
Nutritional supplement Controls and prevents typical 
disorders of pregnancy: low 
back pains, leg cramps, lower 
abdominal pain 
Lack of evidence False 
Famotidine H2 receptor antagonist The most economical anti-ulcer 
in Pakistan 
Cimetidine and ranititidine are 
more economical in Pakistan 
False 
Fosfomycin Antibiotic No drug interaction Significant drug interactions (30) False 
Lisinopril ACE inhibitor The real ACE inhibitor Are captopril or enalapril etc. fake 
inhibitors of ACE? 
False 
Liv. 52 DS  A food supplement FDA approved for 
hepatoprotection 
We could not find any approval on 
the website of FDA 
False 
Loratadine H1-receptor antagonist Provides alertness Lack of evidence False 
Mecobalamin  Recommended in low back pain Lack of evidence False 
Methotrexate Anti-metabolite Rarely associated with side 
effects like bone marrow 
suppression and acute 
disturbances of liver functions 
Frequently associated with bone 
marrow suppression and 
hepatotoxicity (31-34) 
False 
Micronized 
purified 
flavonoidic 
fraction 
 A decisive therapeutic benefit in 
acute hemorrhoidal attacks 
Lack of evidence False 
Naproxen NSAID Is about 20 times more effective 
than aspirin, ibuprofen 
Lack of evidence False / 
exaggerated 
Nimesulide COX 2 inhibitor No drug interactions Although few but significant drug 
interactions have been described 
(35) 
False 
Promethazine + 
pholcodine 
cough 
suppressant 
Anti-histamine/opioid Reduces bronchial congestion 
and spasm of whooping cough 
Lack of evidence False 
Terazosin α-adrenergic blocker The only selective blocker of 
α1-receptors 
Prazosin  and doxazosin are other 
selective blockers 
False 
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3. False Claims (26% of the unjustifiable claims): As 
depicted in Table 3, certain companies were found to 
promote their products on statements that were 
entirely false. For example, we observed a claim on a 
promotional material that methotrexate is rarely 
associated with side effects like bone marrow 
suppression and acute disturbances of liver functions. 
Contrary to this claim, there are various reports, 
which have shown that long term treatment with this 
drug is frequently associated with bone marrow 
suppression and hepatotoxicity (31-34).  
 
 
 
Table 4: List of Controversial promotional claims by pharmaceutical companies in the light of scientific evidence. 
Drug Pharmacological 
Class 
Claim Anti-claim statement Remark 
Cefradine Cephalosporin Resistance to β-lacatamases 
is unmatched by any other 
cephalosporin 
Many other cephalosporins 
are more resistant (36) 
Controversial 
Cetirizine H1-receptor antagonist Remarkable mast cell 
stabilizing effect 
No such effect has been 
observed in many studies (37) 
Controversial/False
Citalopram Anti-depressant No drug interactions Although few but significant 
drug interactions have been 
described (38) 
Controversial 
Citicoline Neuroprotective improves neurocognition Efficacy of long term 
treatment still under 
investigation (39, 40) 
Controversial 
Dihydroergocryptine Dopamine agonist Effective in impotence Lack of evidence Controversial/False
Famotidine H2 receptor antagonist Prevents recurrence of peptic 
ulcer 
Lack of evidence Controversial 
Glibenclamide + 
metphormin 
Sulfonylurea + 
biguanide anti-
diabetic 
A winning combination Higher incidence of mortality 
when treated with the 
combination (41, 42)  
Controversial 
Glucosamine sulphate Natural product Stimulates biosynthesis of 
chondroitin sulphate  
Exogenous glucosamine does 
not stimulate biosynthesis of 
chondroitin sulphate (43) 
Controversial 
Losartan Angiotensin 1 
receptor antagosist 
Better anti-hypertensive 
response as compared to 
valsartan 
Valsartan has been shown to 
be more efficacious (44) 
Controversial 
Mebeverine Anti-spasmodic A safe treatment for Irritable 
Bowel Syndrome 
Hospitalization increased 
after use of mebeverine (45) 
Controversial 
Methotrexate Anti-metabolite Drug of choice for the 
treatment of rheumatoid 
arthritis 
Lack of evidence Controversial 
Nimesulide COX 2 inhibitor Well tolerated by kidneys Death due to nimesulide-
induced renal failure has been 
reported (46) 
Controversial 
Silver sulphadiazine Antibiotic Accelerates wound healing Impairment of wound healing 
has been shown in many 
studies (47) 
Controversial 
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4. Controversial claims (21% of the unjustifiable 
claims): As shown in Table 4, we found that some of 
the promotional material contained claims that have 
not been proven yet. These claims are still under 
investigation. For example, some manufacturers of 
oral hypoglycemic drugs are promoting 
glibenclamide and metformin as a “Winning 
combination”. But the other side of the story is that 
not enough studies have been conducted to prove the 
efficacy of the combination. As a matter of fact few 
of the studies that we came across showed higher 
incidence of mortality in patients treated with the 
combination compared to sulfonylurea alone (41, 42).  
B. Source of information for medical practitioners 
about the drugs 
A total of 150 GPs were contacted personally for 
filling a questionnaire. Out of which 122 GPs 
responded positively (response rate; 81.3%), while 
the rest refused to participate in the study due to one 
or other reasons. All the GPs selected were solo 
private practitioners not affiliated with any hospital 
or group. The characteristics of the GPs, who 
participated in this study, are shown in Table 5.  
 
Table 5: Characteristics of General Practitioners who 
participated in the study (n = 122) 
Characteristics  
Males 82.0% (100) 
Females 18.0% (22) 
Age 39.2 ± 4.5 years 
Years since last degree 10.1 ± 2.4 years 
Mean years of practice 13.3 ± 3.6 years 
No of patients seen per week 132 ± 7.7 
 
The area of study included the cities of Karachi and 
Larkana of the Sindh Province. Since the response of 
GPs from the two cities was not different, the 
answers from all the doctors belonging to both cities 
were pooled together. The doctors were asked to 
identify the primary source of information of the 
drugs for them. As shown in Table 6, the primary 
source of information (approximately 78%) about the 
newly launched drugs for the GPs was found to be 
the pharmaceutical representatives followed by 
hospital doctors (5%) and colleagues (5%) as stated 
by them. Furthermore, 110 (90%) GPs were of the 
view that the drug promotion has definitely an 
influence on their prescribing pattern. Interestingly, 
although 54% of the GPs did not believe completely 
in the advertised claims by the pharmaceutical 
companies, they continued to follow their version and 
prescribed their medications based on the information 
provided by them. 
 
Table 6: Percentage of family physicians’ rating for the 
source of information about the new drugs prescribed by 
him / her 
Source of information about the drugs % (n = 122) 
Medical journal articles 0.8 
Medical books 1.6 
Newspapers 0 
Drug bulletins 0 
Pakistan National Formulary 0 
PharmaGuide / Quick index of medical 
products 
1.6 
Colleagues 4.9 
Consultants 4.9 
Pharmaceutical Representatives 77.9 
Sponsored meetings 3.3 
Direct mail 0 
Journal advertisements 0.8 
Hospital doctors – Discharge letters, patients 
etc. 
4.1 
Internet 0 
DISCUSSION 
This is the first analytic survey of pharmaceutical 
advertising claims in Pakistan. Previous studies have 
shown that medical practitioners are reliant on the 
pharmaceutical industry for much of their drug 
information in Pakistan (48) or elsewhere (49). We 
also observed that despite the apprehensions about 
the truthfulness of the advertised claims, the GPs rate 
the pharmaceutical advertisement as the most 
important source of information about the drugs. 
Furthermore, a majority of physicians are of the view 
that drug marketing has undoubtedly an influence on 
their prescribing practices. The drug promotional 
practices carried out by the pharmaceutical industry 
would have undergone a sea-change from the early 
days. Initially it began as a genuinely informative 
exercise to keep the doctors informed about the 
company’s products. Today it has become more like 
a commercial relationship. Although assessment of 
the truthfulness of the drug promotional claims is 
very complex, we tried to analyze this keeping in 
mind the objectives of the evidence-based medicine. 
Each claim was appraised objectively with the help 
of available evidence in the medical literature. 
 The international pharmaceutical industry is 
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rightly proud of advances made in quality control of 
pharmaceutical production and chemical purity. 
Unfortunately, as many examples in the present 
survey indicate flaws in drug promotional claims, it 
has much less to be proud of in the quality of the 
promotional information. Many of the claims made 
by them were not supported with data. When the text 
of the advertisements was critically evaluated, we 
found a significant ratio (18%) of claims to be 
unjustified or misleading. This carries a marked 
impact on the overall health delivery system. Since 
GPs in Pakistan rate pharmaceutical companies as 
their primary source of information regarding drugs, 
it can be anticipated that inappropriate advertisement 
claims would lead to improper prescribing if 
physicians had no other information on which to 
depend. The outcome of the irrational prescription 
may be that the drugs can be used when these are not 
needed or new, more expensive products are 
prescribed, when these bring no clear advantage over 
cheaper alternatives. The potential health 
consequences for the consumers are not benign; for 
instance, treatment failures from the use of the wrong 
drugs, patients suffering unnecessary adverse effects, 
increase in antibiotic-resistant microorganisms; and 
the waste of patients’ money and national health 
resources. 
 In such a scenario immediate remedial measures 
need to be taken. Starting from the root cause of this 
malpractice, we need to have well-defined and 
updated ethical criteria for the marketing of 
medicinal drugs by the pharmaceutical companies. 
These criteria need to be enforced by a public 
institution, preferably the Ministry of Health. In order 
to ensure that the ethical criteria are being 
implemented, there is a need for screening of printed 
promotional material and active monitoring of other 
forms of promotion. In cases of non-compliance or 
malpractices, effective sanctions and mechanisms to 
correct misinformation should be well-defined. 
 Secondly, we need to teach our doctors the art of 
critical appraisal of medicinal drug promotion 
possibly during their undergraduate training so that 
they would be able to write rational prescriptions. 
Another step towards improvement could be 
reassessing the knowledge of all practicing doctors 
regarding drugs available in the market. This 
assessment should be according to the international 
standards and should be compulsory for the doctor to 
have an attempt after a specified time. This would 
compel the doctors to look up to the authentic 
medical literature for reference instead of relying 
solely on the promotional material. 
 Concluding, the results of the present study show 
that unethical practices regarding the medicinal drug 
promotion are rampant in Pakistan and it is suggested 
that physicians should be cautious and critical in 
assessment of advertised claims of greater efficacy, 
safety or convenience made by the pharmaceutical 
companies. Furthermore, it is high time that efforts 
directed towards an institutionalized implementation 
of ethical criteria for the promotion of drugs be made. 
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